

A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)

Submission date 03/02/2003	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 03/02/2003	Overall study status Completed	☐ Protocol
Last Edited 09/02/2011	Condition category Nervous System Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Harald Murck

Contact details

Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
+44 (0)1786 476001
hmurck@laxdale.co.uk

Additional identifiers

Protocol serial number

LA01.01.0005

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Huntington's disease

Interventions

Two groups randomly allocated to placebo or 2 g/day ethyl EPA on a double blind basis.

Patients who completed the 12 month randomisation phase of the trial were invited to take part in a further 12 month open label phase receiving 2 g/day Ethyl EPA.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/01/2004

Eligibility

Key inclusion criteria

1. Written informed consent
2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance
3. Diagnosis of HD in stage I

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2003

Date of final enrolment

01/01/2004

Locations**Countries of recruitment**

United Kingdom

Scotland

Study participating centre

Laxdale Ltd

Stirling

United Kingdom

FK7 9JQ

Sponsor information**Organisation**

Laxdale Ltd (UK)

ROR

https://ror.org/03gc62f43

Funder(s)

Funder type

Industry

Funder Name

Laxdale Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	26/07/2005		Yes	No